(Just to update my previous post about the liquid biopsy)
Two recently approved liquid biopsy diagnostic tests paired with next-generation sequencing--one developed by Guardant Health and the other by Foundation Medicine--are part of personalized medicine. They identify cancer patients with specific mutations so that they could be benefitted from particular drugs.
The sales of a diagnostic tool would increase the number of cases where a target mutation is identified and thus contribute to the sales of the drug that is used to treat the patients with the mutation. Then, how does the partnership between a diagnostic company and a drug company work? Do they even have a partnership? Does a drug company approach a diagnostic company? Or vice versa?